Neil Desai Purchases Shares of Whitehawk Therapeutics, Inc.

Insider Neil Desai bought 38,040 shares of Whitehawk Therapeutics on June 12, 2026.

Written by EarningsIQ · Published Jun 16, 2026, 2:03 AM EDT · Updated Jun 16, 2026, 1:01 PM EDT

Key Points

Neil Desai purchased 38,040 shares of Whitehawk Therapeutics, Inc. (WHWK) on June 12, 2026.
Whitehawk Therapeutics trades on NasdaqCM at $4.16, with a market cap of $202.8 million and a 52-week range of $1.57 to $5.50.
Analysts like Citizens and Jones Trading have initiated buy ratings with targets up to $8.00.

Neil Desai, an insider at Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK), bought 38,040 shares of the company on June 12, 2026. This transaction highlights insider interest in the company's future prospects.

Insider Buying and Selling at Whitehawk Therapeutics, Inc.

On June 12, 2026, several insiders, including Neil Desai, purchased 38,040 shares each of Whitehawk Therapeutics. These transactions were not part of a pre-planned trading program, indicating a direct interest in increasing their holdings.

Other Institutional Activity in Whitehawk Therapeutics

While Neil Desai and other insiders were buying shares, institutional activity remained stable. QVT Financial LP holds 4,615,709 shares valued at approximately $15.9 million. Similarly, Orbimed Advisors LLC has 4,166,000 shares worth about $14.4 million. Suvretta Capital Management, LLC maintains 3,700,000 shares valued at $12.8 million, and Acuta Capital Partners, LLC holds 3,410,402 shares with an estimated value of $11.8 million. Avero Capital Advisors LLC and KVP Capital Advisors, LP also have significant holdings.

Whitehawk Therapeutics Stock Snapshot

Shares of Whitehawk Therapeutics trade near $4.16 on the Nasdaq Capital Market. The company has a market capitalization of approximately $202.8 million. Despite its negative earnings per share, it has a forward P/E ratio that is not meaningful due to its unprofitability. The stock's 52-week low is $1.57, and its high is $5.50, with a 50-day moving average of $4.15 and a 200-day moving average of $2.98.

Analysts Set New Price Targets

Analysts have shown interest in Whitehawk Therapeutics, with Citizens initiating coverage with a 'buy' rating and an $8.00 price target on April 16, 2026. Jones Trading also started coverage with a 'buy' rating and a $7.00 target on December 22, 2025. The consensus recommendation is a 'buy', with an average target price of $6.50 based on four analyst opinions.

About Whitehawk Therapeutics

Whitehawk Therapeutics, Inc. is a biotechnology company focused on developing treatments for cancer. Based in Morristown, New Jersey, the company specializes in next-generation antibody drug conjugates (ADCs) aimed at improving cancer treatment outcomes. Dr. David J. Lennon leads the company as CEO, with a team of 29 employees dedicated to advancing oncology therapeutics.

Bottom Line

Neil Desai's purchase of shares in Whitehawk Therapeutics signals insider confidence in the company's direction. The stock's recent performance and analyst ratings suggest that the market is taking note of its potential. Investors often watch insider transactions as a sign of internal sentiment, although these moves should not be viewed as investment advice.